Welcome to our dedicated page for Bio Essence SEC filings (Ticker: BIOE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Bio Essence's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Bio Essence's regulatory disclosures and financial reporting.
Bio Essence Corp. filed its Q3 2025 10‑Q, showing stronger operating performance but ongoing financial strain. For the nine months ended September 30, 2025, revenue was $418,112 (up from $176,385), gross profit was $284,992, operating expenses were $414,608, and net loss from continuing operations narrowed to $132,890. For the quarter, revenue was $136,800 with $12,998 net income from continuing operations.
Liquidity remains tight: cash was $28,741, current liabilities were $3,230,021, and the working capital deficit was $3,045,643 as of September 30, 2025. The company reported $885,827 in loans from shareholders and $1,496,907 in current operating lease liabilities. Accumulated deficit reached $10,582,160. Management disclosed that these conditions raise substantial doubt about the ability to continue as a going concern and plans to seek additional financing.
Operations shifted toward OEM services, including a major order from a new customer, supporting revenue growth and margin improvement. Net cash provided by operating activities from continuing operations was $328,701, offset by $301,331 used in financing. Disclosure controls and ICFR were deemed not effective. Common shares outstanding were 38,009,000 as of the latest practicable date.
FAQ
What is the current stock price of Bio Essence (BIOE)?
